NASDAQ:ME 23andMe Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding 23andMe Holding Co. Please log in to your account or sign up in order to add this asset to your watchlist. 2.60 +0.12 (+4.84%) (As of 07/1/2022 08:44 PM ET) Add Compare Share Today's Range2.46▼2.6150-Day Range2.19▼3.2352-Week Range2.12▼13.68Volume1.58 million shsAverage Volume3.61 million shsMarket Capitalization$1.17 billionP/E RatioN/ADividend YieldN/APrice Target5.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media 23andMe Stock Forecast (MarketRank)Analyst RatingModerate Buy2.50 Rating ScoreUpside/Downside92.3% Upside5.00 Price TargetShort InterestHealthy12.56% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.49Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.36 out of 5 starsMedical Sector1035th out of 1,428 stocksPharmaceutical Preparations Industry507th out of 682 stocks 3.3 Analyst's Opinion Consensus Rating23andMe has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of 5.00, 23andMe has a forecasted upside of 92.3% from its current price of 2.60.Amount of Analyst Coverage23andMe has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted12.56% of the float of 23andMe has been sold short.Short Interest Ratio / Days to Cover23andMe has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in 23andMe has recently decreased by 9.78%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend Yield23andMe does not currently pay a dividend.Dividend Growth23andMe does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ME. Previous Next 1.9 News and Social Media Coverage News Sentiment23andMe has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for 23andMe this week, compared to 5 articles on an average week.Search Interest25 people have searched for ME on MarketBeat in the last 30 days. This is an increase of 79% compared to the previous 30 days.MarketBeat FollowsOnly 11 people have added 23andMe to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 23andMe insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 14.14% of the stock of 23andMe is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of 23andMe is -3.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 23andMe is -3.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio23andMe has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 23andMe and its competitors with MarketBeat's FREE daily newsletter. Email Address About 23andMe23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.Read More ME Stock News HeadlinesJuly 1, 2022 | benzinga.comDirect-to-Consumer Genetic Testing Market Size to Grow by USD 1.38 billion | 23andMe Inc. and Alpha Biola - BenzingaJuly 1, 2022 | investorplace.com7 Undervalued Reddit Stocks to Buy Before Wall Street Catches On - InvestorPlaceJune 26, 2022 | americanbankingnews.comHead to Head Analysis: 23andMe (ME) versus Its PeersJune 17, 2022 | finance.yahoo.comThe Funded: Grove Collaborative soars 68% in stock debut after it completed the Bay Area's 8th SPAC merger of 2022June 17, 2022 | bloomberg.com23andMe Takes on Long Covid Impact - BloombergJune 16, 2022 | bizjournals.comOffice sublease space in Silicon Valley, Sunnyvale, 23andme headquarters - Silicon Valley Business Journal - The Business JournalsJune 16, 2022 | nypost.comAmazon Prime Day 2022 preview: When is it and what deals to expect - New York Post June 15, 2022 | seekingalpha.com23andMe: Holiday Miracles Not Enough, Growth Path Too Expensive (NASDAQ:ME) - Seeking AlphaJune 13, 2022 | americanbankingnews.comAnalysts Set 23andMe Holding Co. (NASDAQ:ME) Price Target at 8.00June 12, 2022 | americanbankingnews.com23andMe (NASDAQ:ME) Hits New 12-Month Low at $2.13June 11, 2022 | cnbc.comI talked to 70 parents who raised highly successful kids—here are the 4 hard parenting rules that make them different - CNBCJune 9, 2022 | bizjournals.comThursday Digest: Mission Bay residents sue; Twitter details timeline for Musk deal - San Francisco Business Times - The Business JournalsJune 8, 2022 | bizjournals.com23andMe shifts headquarters from Sunnyvale to South San Francisco - Silicon Valley Business Journal - The Business JournalsJune 8, 2022 | finance.yahoo.com23andMe has officially moved and downsized its HQJune 5, 2022 | forbes.comBill Gates And Melinda French Gates Both At Giving Pledge Gathering, But No Sign Of Warren Buffett Or MacKenzie Scott - ForbesJune 2, 2022 | finance.yahoo.comWomen, people with high cholesterol have higher risk for long COVID, according to 23andMeJune 2, 2022 | finance.yahoo.comFormer 23andMe Principal Data Scientist Mike Macpherson Joins Carbon Management Platform nZero as Vice President of Data Science to Further Company's Focus on Accurate and Actionable Data Insights - Yahoo FinanceJune 1, 2022 | finance.yahoo.comHeart conditions and gender may increase the risk for long COVID, according to 23andMeMay 28, 2022 | ca.investing.com23andMe Holding Co. Misses Q4 EPS by 3c By Investing.com - Investing.com CanadaMay 28, 2022 | benzinga.com23andMe shares are trading lower after the company reported worse-than-expected Q1 sales results and issu - BenzingaMay 27, 2022 | benzinga.comCredit Suisse Maintains Outperform on 23andMe Holding, Lowers Price Target to $7 - Benzinga - BenzingaMay 26, 2022 | seekingalpha.com23andMe GAAP EPS of -$0.16 misses by $0.01, revenue of $100.56M misses by $2.23M (NASDAQ:ME) - Seeking AlphaMay 26, 2022 | marketwatch.com23andMe stock falls on widening loss - MarketWatchMay 26, 2022 | finance.yahoo.com23andMe stock falls on widening lossMay 26, 2022 | investing.com23andMe Holding Co. Misses Q4 EPS by 3c By Investing.com - Investing.comSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ME CUSIPN/A CIK1804591 Webvgacquisition.com Phone650-938-6300FaxN/AEmployees572Year FoundedN/ACompany Calendar Last Earnings5/26/2022Today7/02/2022Next Earnings (Estimated)8/12/2022Fiscal Year End3/31/2023Price Target and Rating Average Stock Price Forecast5.00 High Stock Price Forecast7.00 Low Stock Price Forecast3.00 Forecasted Upside/Downside+92.3%Consensus RatingModerate Buy Rating Score (0-4)2.5 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)-0.66 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-217.49 million Net Margins-79.99% Pretax Margin-81.27% Return on Equity-25.41% Return on Assets-19.22% Debt Debt-to-Equity RatioN/A Current Ratio3.93 Quick Ratio3.86 Sales & Book Value Annual Sales$271.89 million Price / Sales4.30 Cash FlowN/A Price / Cash FlowN/A Book Value2.04 per share Price / Book1.27Miscellaneous Outstanding Shares449,173,000Free FloatN/AMarket Cap$1.17 billion OptionableNot Optionable Beta1.45 23andMe Frequently Asked Questions Should I buy or sell 23andMe stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 23andMe in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" 23andMe stock. View analyst ratings for 23andMe or view top-rated stocks. What is 23andMe's stock price forecast for 2022? 2 analysts have issued 1-year target prices for 23andMe's stock. Their ME stock forecasts range from 3.00 to 7.00. On average, they anticipate 23andMe's share price to reach 5.00 in the next twelve months. This suggests a possible upside of 92.3% from the stock's current price. View analysts' price targets for 23andMe or view top-rated stocks among Wall Street analysts. How has 23andMe's stock performed in 2022? 23andMe's stock was trading at 6.66 at the beginning of 2022. Since then, ME stock has decreased by 61.0% and is now trading at 2.60. View the best growth stocks for 2022 here. When is 23andMe's next earnings date? 23andMe is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for 23andMe. How were 23andMe's earnings last quarter? 23andMe Holding Co. (NASDAQ:ME) announced its earnings results on Thursday, May, 26th. The company reported ($0.13) earnings per share (EPS) for the quarter. The firm earned $100.56 million during the quarter, compared to analysts' expectations of $102.79 million. 23andMe had a negative trailing twelve-month return on equity of 25.41% and a negative net margin of 79.99%. The firm's revenue for the quarter was up 13.5% compared to the same quarter last year. View 23andMe's earnings history. What guidance has 23andMe issued on next quarter's earnings? 23andMe issued an update on its FY 2023 earnings guidance on Thursday, June, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $260.00 million-$280.00 million, compared to the consensus revenue estimate of $339.87 million. Who are 23andMe's key executives? 23andMe's management team includes the following people: Ms. Anne Wojcicki, Co-Founder, CEO, Pres & DirectorMr. Steven J. Schoch, Chief Financial and Accounting Officer (Age 63, Pay $582.83k)Ms. Kathy L. Hibbs Esq., J.D., Chief Admin. Officer (Age 58, Pay $558.53k)Dr. Kenneth J. Hillan Ch.B., M.B., Chief Therapeutics Officer (Age 61, Pay $557.62k)Dr. Joseph R. Arron M.D., Ph.D., Chief Scientific OfficerDr. Wade Walke, VP of Investor Relations (Age 56)Ms. Jacquie Cooke Haggarty J.D., Gen. Counsel & Privacy OfficerMs. Katie Watson, VP of Communications (Age 44)Mr. Fred Mark Kohler, VP of People (Age 55)Mr. Mike Polcari, VP & Chief Architect (Age 41) Who are some of 23andMe's key competitors? Some companies that are related to 23andMe include Hypera (HYPMY), Ultragenyx Pharmaceutical (RARE), Evotec (EVTCY), Mirati Therapeutics (MRTX), Cerevel Therapeutics (CERE), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Galapagos (GLPG), Cytokinetics (CYTK), Bausch Health Companies (BHC), Harmony Biosciences (HRMY), AbCellera Biologics (ABCL) and Amicus Therapeutics (FOLD). View all of ME's competitors. What is 23andMe's stock symbol? 23andMe trades on the NASDAQ under the ticker symbol "ME." How do I buy shares of 23andMe? Shares of ME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is 23andMe's stock price today? One share of ME stock can currently be purchased for approximately 2.60. How much money does 23andMe make? 23andMe (NASDAQ:ME) has a market capitalization of $1.17 billion and generates $271.89 million in revenue each year. The company earns $-217.49 million in net income (profit) each year or -0.66 on an earnings per share basis. How many employees does 23andMe have? 23andMe employs 572 workers across the globe. How can I contact 23andMe? 23andMe's mailing address is 65 BLEECKER STREET 6TH FLOOR, NEW YORK NY, 10012. The official website for 23andMe is vgacquisition.com. The company can be reached via phone at 650-938-6300 or via email at investors@23andme.com. This page (NASDAQ:ME) was last updated on 7/2/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
